Journal
JOURNAL OF PATHOLOGY
Volume 223, Issue 2, Pages 230-240Publisher
WILEY
DOI: 10.1002/path.2788
Keywords
lung cancer; signal transduction pathway; gene mutation; protein kinase; targeted therapy; genetic analysis; sequencing; gene fusion; gene rearrangement
Funding
- Xcovery
Ask authors/readers for more resources
Knowledge of tumour mutation status has become increasingly important for the prioritization of targeted therapies for cancer. We review here the major known 'driver' mutations with therapeutic relevance in non-small cell lung cancer. We also discuss a variety of methods now being employed in molecular diagnostic laboratories to detect genetic alterations in lung tumours. A genetically-informed approach to lung cancer medicine is rapidly becoming the standard of care worldwide and should lead to improved outcomes for patients. Copyright (C) 2010 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available